---
title: Coverage with Evidence Development: Reimbursement While You Generate Evidence
description: How coverage with evidence development (CED) lets MedTech startups get reimbursed while generating the clinical data payers demand.
authors: Tibor Zechmeister, Felix Lenhard
category: Funding, Business Models & Reimbursement
primary_keyword: coverage with evidence development medical device
canonical_url: https://zechmeister-solutions.com/en/blog/coverage-with-evidence-development-ced
source: zechmeister-solutions.com
license: All rights reserved. Content may be cited with attribution and a link to the canonical URL.
---

# Coverage with Evidence Development: Reimbursement While You Generate Evidence

*By Tibor Zechmeister (EU MDR Expert, Notified Body Lead Auditor) and Felix Lenhard.*

> **Coverage with evidence development (CED) is a reimbursement arrangement where a payer agrees to pay for a medical device conditionally, provided the manufacturer collects additional clinical or economic evidence during routine use. For MedTech startups, CED can be the difference between first revenue at year three or year six. The catch is that it binds your post-market surveillance obligations under MDR Articles 83 to 86 tightly to your commercial survival.**

**By Tibor Zechmeister and Felix Lenhard.**

## TL;DR
- Coverage with evidence development (CED) is a conditional reimbursement mechanism where a payer pays for a device while the manufacturer continues to collect agreed-upon evidence.
- CED exists in various forms across EU Member States — Germany's §137e and §137h pathways for new examination and treatment methods, France's forfait innovation, England's managed access agreements, Italy's registry-based conditional reimbursement — with substantially different rules per country. 
- CED evidence generation overlaps heavily with MDR post-market clinical follow-up under Annex XIV Part B and post-market surveillance under Articles 83 to 86. A single well-designed programme can serve both.
- Exit criteria matter more than entry criteria. Read the contract carefully: what evidence, by when, judged how, with what consequence if the result is negative.
- CED is not a way to bypass evidence — it is a way to sequence it. Payers who offer CED expect rigorous data collection and will withdraw coverage if the manufacturer underdelivers.
- For startups, CED is most useful when standard HTA evidence requirements are unachievable pre-launch but the device has strong preliminary clinical data and a clear unmet need.

## Why CED matters for MedTech startups

There is a familiar deadlock in MedTech reimbursement. The payer says: "We will pay for this device once you show us real-world outcomes data from hundreds of patients." The startup says: "We cannot generate real-world data from hundreds of patients until we have revenue to fund the studies." Both statements are rational. Together they are a trap.

Coverage with evidence development is the lever that breaks the deadlock. In a CED arrangement, the payer agrees to reimburse the device (usually at a negotiated price, sometimes below the target price) on the condition that the manufacturer commits to collecting specified data — typically through a registry, a prospective observational study, or a linked PMCF programme — within an agreed time window. At the end of the window, the evidence is reviewed and the payer decides whether to grant permanent reimbursement, renegotiate, or withdraw coverage.

For a cash-constrained startup, CED can turn a binary "no reimbursement until you have evidence" into a graduated path: conditional revenue now, full revenue later, with evidence generated as a by-product of real-world use. Done well, it compresses the timeline to sustainable revenue by years. Done badly, it locks a startup into an evidence programme it cannot afford to deliver.

Tibor has seen both outcomes. The deciding factor is almost always how carefully the manufacturer reads the exit criteria before signing, and how tightly the CED data collection is integrated with the MDR PMS and PMCF programme from day one.

## What MDR actually says about CED

Nothing. CED is a reimbursement construct, not a regulatory one. Regulation (EU) 2017/745 does not define, require, or forbid CED. However, the MDR articles that govern post-market evidence generation are the same articles that govern most CED evidence obligations in practice:

- **Article 61 and Annex XIV Part A** define the clinical evaluation obligation. This is the baseline evidence your notified body needs before CE mark — CED typically starts *after* this baseline is met, not instead of it.
- **Articles 83 to 86** define the post-market surveillance system obligation: a proactive, systematic procedure to gather and analyse data on device performance and safety throughout its lifetime. CED data collection feeds directly into this obligation.
- **Annex XIV Part B** defines post-market clinical follow-up. PMCF is the clinical component of PMS, and for many device classes PMCF is mandatory regardless of reimbursement status. A CED registry is, in practice, an enhanced PMCF study.
- **Article 86** defines the Periodic Safety Update Report (PSUR) obligation for Class IIa, IIb, and III devices. PSUR content overlaps substantially with CED reporting to payers.

The practical consequence: if your PMS and PMCF programme is well designed, a CED arrangement should add minimal incremental evidence-generation burden. If your PMS programme is weak, CED will expose that weakness, because payers read CED reports with the same scepticism as notified body reviewers — sometimes more.

## CED across European markets: the landscape

CED-style mechanisms exist in many EU Member States under different names and with substantially different rules. A startup considering CED must check the current national framework — these systems evolve.

**Germany.** The §137e SGB V pathway allows conditional reimbursement for new examination and treatment methods (neue Untersuchungs- und Behandlungsmethoden, NUB) in the inpatient context, contingent on evidence generation during a defined testing period. The §137h pathway applies specifically to high-risk methods involving medical devices of high risk class. 

**France.** The forfait innovation mechanism allows conditional reimbursement for innovative devices meeting specific criteria, managed by HAS in coordination with the Ministry of Health, with explicit evidence generation requirements. 

**England.** Outside the EU but relevant to many founders: NICE and NHS England operate managed access agreements, including the Innovative Medicines Fund and, historically, the Cancer Drugs Fund model which has partial device applicability. 

**Italy.** Registry-based conditional reimbursement mechanisms operate at both national (AIFA for some device-adjacent products) and regional level, with evidence generation tied to device registries. 

**Netherlands and Belgium.** Both operate conditional reimbursement mechanisms for innovative devices under their respective national health insurance systems, with evidence generation requirements negotiated case by case. 

The details differ. The pattern is consistent: conditional payment now, evidence later, binary decision at the end of a defined window. A startup should never assume a CED mechanism in one country looks like the one next door.

## A worked example

A startup has a CE-marked Class IIb implantable device for a rare cardiac condition. Pilot data from 40 patients shows a 35% reduction in hospital readmissions at 12 months compared with historical controls. The formal HTA bar in Germany would require a randomised controlled trial with at least several hundred patients — unachievable within the startup's runway.

The startup negotiates a §137e-style arrangement: the payer agrees to reimburse the device at 80% of target price for a defined cohort of up to 300 patients over three years, contingent on the manufacturer operating a prospective registry that captures readmission rates, mortality, device-related complications, and quality of life at 6, 12, and 24 months. At the end of year three, an independent assessment determines whether the real-world evidence supports permanent reimbursement at full price, price renegotiation, or withdrawal. 

What the startup does right:

1. The registry protocol is designed as a single document serving three audiences: the payer's evidence requirements, the MDR PMCF obligation under Annex XIV Part B, and the PSUR obligation under Article 86. One data collection, three reports.
2. The endpoints in the registry match the endpoints in the payer's exit criteria. No ambiguity about what "success" means at year three.
3. The cost of running the registry is budgeted explicitly against the 80% reimbursement revenue. Gross margin at 80% still covers registry operating costs plus a small positive contribution.
4. The contract includes a clear data cutoff, a clear decision procedure, and a clear fallback if the evidence is ambiguous rather than binary.

What the same startup almost did wrong: in the initial draft, the registry had different endpoints from the CED exit criteria, creating a risk that the manufacturer would generate data the payer did not accept. Catching this before signing saved the company.

## The Subtract to Ship playbook for CED

CED is a powerful tool for startups — and a dangerous one if used carelessly. Five moves make it survivable.

**1. Never sign a CED without a cash flow model.** Work out what the conditional price, at expected volume, pays you — and whether that is enough to operate the registry, run PMS and PMCF, and keep the lights on. A CED deal that does not cover its own evidence costs is a slow-motion bankruptcy.

**2. Design the registry once, serve three audiences.** The registry must simultaneously satisfy the CED exit criteria, MDR PMCF obligations under Annex XIV Part B, and PSUR content requirements under Article 86. Build one protocol, one data dictionary, one governance structure. Anything else doubles your cost for no commercial benefit.

**3. Read the exit criteria like a lawyer.** What is the decision rule at the end of the CED window? Who makes it? On what evidence? With what appeal path? If the contract says "at the payer's discretion" without a defined rule, you are signing a blank cheque. Push back until the exit rule is specific.

**4. Build a data infrastructure that works under audit.** CED data becomes part of your PMS file, which notified bodies review. Ensure audit-ready data capture, version control, and traceability from the first patient. Retrofitting data quality later is expensive and often impossible.

**5. Plan for the post-CED transition from day one.** What happens if the evidence is positive? Full price and a renegotiated framework contract. What if it is neutral? Price reduction or extended CED. What if it is negative? Withdrawal, inventory write-down, reputational damage. Have a financial and regulatory plan for all three scenarios before signing.

## Reality Check

1. Have you identified which specific national CED mechanism applies to your device, and verified its current rules?
2. Is the conditional reimbursement price, at realistic volume, sufficient to fund both your operations and the CED evidence programme?
3. Are your CED evidence endpoints identical to your PMCF endpoints under Annex XIV Part B?
4. Do you have a clear, written exit rule from the CED contract — or is the decision at the payer's discretion?
5. Can your data infrastructure survive a notified body audit of PMS and PMCF data quality?
6. Do you know what happens commercially and regulatorily if the CED outcome is negative?
7. Is your team resourced for three years of continuous registry operation, not just the first six months?
8. Have you modelled the scenario where CED evidence is ambiguous rather than clearly positive or negative?

## Frequently Asked Questions

**Is CED a way to avoid generating clinical evidence?**
No. CED sequences evidence generation differently, but the total evidence burden is often higher, not lower, than a traditional HTA path. The advantage is cash flow, not evidence reduction.

**Does CED replace the need for a CE mark?**
No. A CED arrangement starts after CE mark. You still need to meet the full MDR requirements, including clinical evaluation under Article 61 and Annex XIV, before any payer conversation begins.

**Can a startup negotiate CED directly with a payer?**
In most countries, yes — though the process is formal, slow, and often requires an academic or clinical partner to sponsor the registry. Expect negotiations to take 6 to 18 months.

**What happens to the MDR PSUR if CED data shows a safety signal?**
The safety signal must be reported through vigilance channels under Articles 87 to 92 regardless of CED status. The CED contract does not override MDR safety reporting obligations — ever.

**Is CED used for Class I devices?**
Rarely. CED mechanisms typically target higher-risk, higher-cost innovations where the evidence burden is substantial. For Class I devices, the commercial path is usually direct sales without formal reimbursement negotiation.

**What is the biggest mistake startups make with CED?**
Signing a deal where the conditional price does not cover the cost of the evidence programme. The result is a startup working hard to deliver data it cannot afford to collect. Always model the cash flow first.

## Related reading
- [HTA Submissions for Medical Devices](/blog/hta-submissions-medical-devices) — how formal HTA interacts with CED pathways.
- [Health Economic Evaluation for Medical Devices](/blog/health-economic-evaluation-medical-devices) — the economic modelling that underpins most CED decisions.
- [PMCF Guide for Startups](/blog/pmcf-mdr-guide-startups) — how post-market clinical follow-up integrates with CED registries.
- [PMS Data Updates to Clinical Evaluation](/blog/pms-data-updates-clinical-evaluation) — the MDR feedback loop that CED data feeds into.
- [Health Insurance Reimbursement in Europe](/blog/health-insurance-reimbursement-europe) — the broader payer landscape CED sits inside.

## Sources
1. Regulation (EU) 2017/745 on medical devices, consolidated text. Articles 61, 83–86, 87–92, Annex XIV Parts A and B.
2. National reimbursement legislation per Member State — §137e and §137h SGB V (Germany), forfait innovation framework (France), NICE managed access agreements (England). 
3. MDCG 2025-10 (December 2025) — Post-market surveillance guidance.

---

*This post is part of the [Funding, Business Models & Reimbursement](https://zechmeister-solutions.com/en/blog/category/funding-reimbursement) cluster in the [Subtract to Ship: MDR Blog](https://zechmeister-solutions.com/en/blog). For EU MDR certification consulting, see [zechmeister-solutions.com](https://zechmeister-solutions.com).*